The drugmakers developing the vaccine candidates now in the final stage of clinical testing — Pfizer, Moderna, AstraZeneca and Johnson & Johnson — all told Business Insider they plan to test their vaccines in children, but none gave an estimated timeline of when a vaccine could become available for children.
Moderna shared its plans to begin a pediatric trial with Business Insider, saying it hopes to get one underway by the end of 2020, pending regulatory approval.
“Right now I’m pretty worried that we won’t have a vaccine available for kids by the start of next school year,” Evan Anderson, MD, an Atlanta pediatrician, told The New York Times.
More articles on pharmacy:
Novartis sells $2.1B in bonds to increase access to its drugs in disadvantaged countries
FDA proposes change to rule on off-label drug use
Gilead settles kickback allegations for $97M
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
